China Healthcare Weekly (Aug.18)- COVID Is Here, BIOSECURE Act Update, Livzon Deserves More Patience
COVID is coming again. So investors can focus on related stocks. US companies leaving Chinese partners due to BIOSECURE Act. Livzon is still worth...
Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series – Part 4
Different provinces expand coverage for assisted reproductive services in medical insurance. Livzon missed expectation in 2023.US sanction on BGI...
Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series - Part 3
We updated the most recent changes in relevant fertility support policies in China. Meanwhile, we also analyzed our views on the performance and...
Smartkarma Originals
China Population Policies Impact on Healthcare Companies Series – Part 2
Several regions have successively introduced policies to encourage childbirth, so we analyzed the recent policy updates. Based on Livzon/BGI...
Smartkarma Originals